SynthesisESMO open2020

Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.

Jian-Guo Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.